Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB – Research Report) and Simulations Plus (SLP – Research Report).
Biogen (BIIB)
In a report released yesterday, Thomas Shrader from BTIG maintained a Hold rating on Biogen. The company’s shares closed last Thursday at $284.99.
According to TipRanks.com, Shrader is a 1-star analyst with an average return of
Biogen has an analyst consensus of Strong Buy, with a price target consensus of $340.83, a 19.2% upside from current levels. In a report issued on June 23, Bank of America Securities also maintained a Hold rating on the stock with a $320.00 price target.
See the top stocks recommended by analysts >>
Simulations Plus (SLP)
BTIG analyst David Larsen maintained a Buy rating on Simulations Plus yesterday and set a price target of $55.00. The company’s shares closed last Thursday at $41.29.
According to TipRanks.com, Larsen ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Simulations Plus has an analyst consensus of Strong Buy, with a price target consensus of $61.00, implying a 41.3% upside from current levels. In a report issued on June 30, Craig-Hallum also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BIIB:
- Biogen, Eisai’s Alzheimer’s Drug Scores Big With FDA’s Full Approval
- FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
- Biogen announces new SPINRAZA data
- New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
- Piper Sandler pharmaceuticals analysts to hold analyst/industry conference call
